Is NCT05489211 recruiting in San Diego, CA?

Yes, NCT05489211 is currently recruiting participants at its San Diego, CA location. This advanced solid tumors clinical trial is actively enrolling qualified participants.

How do I join the advanced solid tumors clinical trial in San Diego?

To join this clinical trial in San Diego, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this San Diego clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Advanced Solid Tumors Clinical Trial in San Diego, CA

Who Can Participate

Inclusion Criteria

There are additional substudy requirements not reflected here. This list is based solely on the master CSP

Male and female, ≥ 18 years

Documented advanced or metastatic malignancy

Eastern Cooperative Oncology Group performance status of 0 or 1 with no deterioration over the 2 weeks prior to baseline or day of first dosing

All participants must provide a tumour sample for tissue-based analysis

At least 1 measurable lesion not previously irradiated, except Substudy 3 (Prostate Cancer) which allows participants with non measurable bone metastatic disease

Adequate bone marrow reserve and organ function

Minimum life expectancy of 12 weeks

At the time of screening, contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies

All women of childbearing potential must have a negative serum pregnancy test documented during screening

Female participants must be 1 year post-menopausal, surgically sterile, or using 1 highly effective form of birth control. Female participants must not donate, or retrieve for their own use, ova at any time during this study

Male participants who intend to be sexually active with a female partner of childbearing potential must be surgically sterile, avoid intercourse, or use a highly effective method of contraception. Male participants must not freeze or donate sperm at any time during this study.

Capable of giving signed informed consent

Provision of signed and dated written optional genetic research informed consent prior to collection of samples for optional genetic research that supports the Genomic Initiative Key

Exclusion Criteria

Any evidence of diseases which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol

History of another primary malignancy except for adequately resected basal cell carcinoma or in situ squamous cell carcinoma of the skin, or other solid malignancy treated with curative intent

Persistent toxicities caused by previous anticancer therapy, excluding alopecia, not yet improved

Irreversible toxicity that is not reasonably expected to be exacerbated by study intervention in the opinion of the investigator, for example hearing loss

Spinal cord compression or brain metastases unless treated

Leptomeningeal carcinomatosis

Clinically significant corneal disease

Active hepatitis or uncontrolled hepatitis B or C virus infection

Uncontrolled infection requiring IV antibiotics, antivirals or antifungals, for example prodromal symptoms

Known HIV infection that is not well controlled

Known active tuberculosis infection

Mean resting corrected QTcF \> 470 ms

In the judgement of the investigator, history of QT prolongation associated with other medications that required discontinuation of that medication, or any current concomitant medication known to prolong the QT interval and cause TdP

In the judgement of the investigator, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives

Uncontrolled or significant cardiac diseases

History of non-infectious Interstitial lung disease (ILD)/pneumonitis, including radiation pneumonitis that required steroids

Has severe pulmonary function compromise

Prior exposure to chloroquine/hydroxychloroquine without an adequate treatment washout period

Receipt of live, attenuated vaccine within 30 days prior to the first dose of study intervention

Prior exposure to anticancer therapies without an adequate treatment washout period prior to enrolment or any concurrent anticancer treatment

Palliative radiotherapy with a limited field of radiation within ≤ 2 weeks or to more than 30% of the bone marrow within ≤ 4 weeks before the first dose of study intervention

Major surgical procedure or significant traumatic injury within ≤ 3 weeks of the first dose of study intervention or an anticipated need for major surgery during the study

Prior treatment with TROP2-directed therapies or other antibody-drug conjugate (ADCs) with deruxtecan payload

Herbal or natural products intended as treatment or prophylaxis for any type of cancer that may interfere with the activity of the study intervention

Previous treatment in the present study

Participation in another clinical study with a study intervention or investigational medicinal device administered in the last 4 weeks prior to first dose of study intervention or concurrent enrolment in another clinical study

Severe hypersensitivity to Dato-DXd or any of the excipients, including but not limited to polysorbate 80 or other monoclonal antibodies

Involvement in the planning and/or conduct of the study

Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements

Females that are pregnant, breastfeeding, or planning to become pregnant

Female participants should refrain from breastfeeding from enrolment throughout the study and for at least 7 months after last dose of Dato-DXd

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in San Diego?

Yes, this clinical trial (NCT05489211) has an active research site in San Diego, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Advanced Solid Tumors Treatment Options in San Diego, CA

If you're searching for advanced solid tumors treatment options in San Diego, CA, this clinical trial (NCT05489211) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our San Diego research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced advanced solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all advanced solid tumors clinical trials near you to find additional studies recruiting in your area.

Advanced Solid Tumors Clinical Trial in San Diego, CA

Expert Care in San Diego

IRB Approved

No-Cost Care

Apply for This San Diego Location

Why Participate?

Simple Process

About This Advanced Solid Tumors Study in San Diego